Peptidoglycan-Chi3l1 interaction shapes gut microbiota in intestinal mucus layer
eLife assessment
Supported by convincing data, this valuable study demonstrates that the Chitinase 3-like protein 1 (Chi3l1) interacts with gut microbiota and protects animals from intestinal injury in laboratory colitis model. The revised article sufficiently addressed the reviewers' comments. The work will be of interest to scientists studying crosstalk between gut microbiota and inflammatory diseases.
https://doi.org/10.7554/eLife.92994.3.sa0Valuable: Findings that have theoretical or practical implications for a subfield
- Landmark
- Fundamental
- Important
- Valuable
- Useful
Convincing: Appropriate and validated methodology in line with current state-of-the-art
- Exceptional
- Compelling
- Convincing
- Solid
- Incomplete
- Inadequate
During the peer-review process the editor and reviewers write an eLife Assessment that summarises the significance of the findings reported in the article (on a scale ranging from landmark to useful) and the strength of the evidence (on a scale ranging from exceptional to inadequate). Learn more about eLife Assessments
Abstract
The balanced gut microbiota in intestinal mucus layer plays an instrumental role in the health of the host. However, the mechanisms by which the host regulates microbial communities in the mucus layer remain largely unknown. Here, we discovered that the host regulates bacterial colonization in the gut mucus layer by producing a protein called Chitinase 3-like protein 1 (Chi3l1). Intestinal epithelial cells are stimulated by the gut microbiota to express Chi3l1. Once expressed, Chi3l1 is secreted into the mucus layer where it interacts with the gut microbiota, specifically through a component of bacterial cell walls called peptidoglycan. This interaction between Chi3l1 and bacteria is beneficial for the colonization of bacteria in the mucus, particularly for Gram-positive bacteria like Lactobacillus. Moreover, a deficiency of Chi3l1 leads to an imbalance in the gut microbiota, which exacerbates colitis induced by dextran sodium sulfate. By performing fecal microbiota transplantation from Villin-cre mice or replenishing Lactobacillus in IEC∆Chil1 mice, we were able to restore their colitis to the same level as that of Villin-cre mice. In summary, this study shows a ‘scaffold model’ for microbiota homeostasis by interaction between intestinal Chi3l1 and bacteria cell wall interaction, and it also highlights that an unbalanced gut microbiota in the intestinal mucus contributes to the development of colitis.
Introduction
Intestinal homeostasis is crucial for maintaining human health (Lozupone et al., 2012). Alterations in gut microbiota composition have been linked to various diseases including cancer, obesity, and neurological disorders (Bäumler and Sperandio, 2016; Charbonneau et al., 2016; Honda and Littman, 2016; Sonnenburg and Bäckhed, 2016; Thaiss et al., 2016). Dysbiosis, which refers to an imbalance in gut microbiota, is characterized by decreased microbial diversity, the presence of harmful microbes, or absence of beneficial ones (Petersen and Round, 2014). Therefore, understanding the factors that influence gut microbiota is a fundamental goal in microbiome research (McDonald et al., 2020). Growing evidence suggests that colonization of the gut mucus layer can affect the susceptibility and progression of intestinal diseases like inflammatory bowel disease (IBD), irritable bowel syndrome, and celiac disease (Gordon, 2012). IBDs, such as Crohn’s disease (CD) and ulcerative colitis (UC), are characterized by chronic inflammation of the intestinal mucosa. Although the cause of the IBD is unclear, mouse models lacking the key components of the mucus are predisposed to colitis, accompanied by dysbiosis in mucosa (Fu et al., 2011; Johansson et al., 2008), which is in accordance with increased epithelial-adherent microbial communities in biopsies from patients with IBD (Johansson et al., 2014; Swidsinski et al., 2005). Furthermore, there were significant differences in the gut microbiota of CD patients compared with healthy controls, and these differences were only present in mucus samples (not stool samples), suggesting that bacteria in the mucus layer may be more important for the development of IBD (Gevers et al., 2014). Donaldson et al. discovered that the intestinal flora utilizes host immunoglobulin A (IgA) for mucus colonization, indicating that the host may secrete certain factors to maintain intestinal flora homeostasis in the mucus (Donaldson et al., 2018). However, the mechanisms regulating gut microbiota colonization in the mucus layer remain largely unknown. We aim to investigate the regulation of microbial communities in gut mucus and its implications in intestinal diseases.
Chitinase 3-like protein 1 (Chi3l1, also known as YKL-40 in humans) is a secreted protein that belongs to the glycosylhydrolase 18 family (Lee et al., 2011). Despite its name, Chi3l1 can bind to chitin but does not have chitinase activity (Houston et al., 2003). In our investigation, we noticed that chitin and peptidoglycan (PGN), a major component of bacterial cell walls, have similar structures (Fulde et al., 2018). Based on this information, we speculate that Chi3l1 might also interact with PGN and, therefore, interact with bacteria. Interestingly, Chi3l1 is expressed in intestinal epithelial cells (IECs) and the lamina propria. We hypothesize that Chi3l1 may be secreted by IECs and regulate the gut microbiota through its interaction with PGN in the mucus layer. In our study, we discovered that gut microbiota induced the expression of Chi3l1 in epithelial cells. Once expressed, Chi3l1 is secreted into the mucosa and interacts with bacteria, particularly with the bacterial cell wall component PGN. This interaction promotes bacterial colonization, especially of beneficial bacteria such as Lactobacillus. As a result, mice with higher levels of Chi3l1 are less susceptible to colitis.
Results
Intestinal epithelial cells express Chi3l1 induced by gut microbiota
The gut microbiota’s composition is shaped by host factors, including IgA (Donaldson et al., 2018), RegIIIγ (Vaishnava et al., 2011), and TLR-5 (Fulde et al., 2018). Yet, specific host factors which maintain the homeostasis of the microbiota remain largely undefined. Drawing on the theory of co-evolution between the host and microbiota (Groussin et al., 2020), we propose that host factors, which are induced by bacteria in the gut, could play a pivotal role in regulating bacterial colonization and composition. In a previous study, it was observed that both live Escherichia coli and heat-killed E. coli treatment resulted in a significant increase in the expression of the gene encoding Chi3l1 in human intestinal organoids (Hill et al., 2017). To verify this finding, we conducted immunohistochemical staining on intestinal tissue sections of germ-free and specific pathogen free (SPF) C57BL/6J wildtype mice. We observed a substantial increase of Chi3l1 expression in SPF mice compared to germ-free mice (Figure 1A). The intestinal epithelium comprises various cell types, including intestinal cells, goblet cells, endoentercrine cells, Tuft cells, Paneth cells, M cells, and others (Johansson et al., 2014). To identify the cellular sources of Chi3l1, we performed co-staining with markers for specific cell types, including chromogranin A (ChgA) for enteroendocrine cells, Ulex europaeus Agglutinin I (UEA-1) for goblet cells and Paneth cells, and double cortin-like kinase 1 (DCLK1) for tuft cells. Our results revealed that Chi3l1 is primarily expressed in enteroendocrine cells in the ileum and goblet or Paneth cells in the colon (Figure 1B). However, Chi3l1 expression was not observed in tuft cells (Figure 1—figure supplement 1A).
-
Figure 1—source data 1
- https://cdn.elifesciences.org/articles/92994/elife-92994-fig1-data1-v1.zip
-
Figure 1—source data 2
- https://cdn.elifesciences.org/articles/92994/elife-92994-fig1-data2-v1.zip
-
Figure 1—source data 3
- https://cdn.elifesciences.org/articles/92994/elife-92994-fig1-data3-v1.xlsx
Furthermore, we isolated total bacteria from wildtype mouse feces and treated DLD-1 cells (a colorectal adenocarcinoma cell line) with the bacterial extract for 12 hr. We found that the bacterial extract directly induced Chi3l1 expression in DLD-1 cells (Figure 1C). To examine whether the induction of Chi3l1 expression requires a specific bacteria strain, we further identified the bacterial extract using 16S rRNA sequencing. Our results revealed that E. coli specifically stimulated Chi3l1 expression in DLD-1 cells, while Staphylococcus sciuri did not have the same effect (Figure 1D). Although our data are limited to these two bacterial strains, it suggests that not all bacteria can induce the expression of Chi3l1. Next, we wondered what component of bacteria can induce Chi3l1 expression. We tried heat-killed E. coli, which maintains bacterial cell wall integrity. We found that treatment of DLD-1 cells with heat-killed E. coli also led to an induction of Chi3l1 expression (Figure 1E). These findings suggest that the induction of Chi3l1 expression does not necessarily require live bacteria and that bacterial components alone are sufficient to induce this response.
Given that E. coli is Gram-negative and S. sciuri is Gram-positive, we hypothesized that the difference in their ability to induce Chi3l1 expression might be due to variations between Gram-negative and Gram-positive bacteria, such as the presence of lipopolysaccharides (LPS). To test this hypothesis, we used LPS to induce Chi3l1 expression. Consistent with our hypothesis, LPS successfully induced Chi3l1 expression (Figure 1F and G). Collectively, these findings provide evidence that the gut microbiota can induce Chi3l1 expression in IECs. Collectively, these findings provide evidence that the gut microbiota can induce Chi3l1 expression in IECs.
Chi3l1 interact with bacteria via peptidoglycan
Chi3l1 belongs to a group of proteins called non-enzymatic chitinase-like proteins, which are known to bind chitin. Chitin is a polysaccharide present in the exoskeleton of arthropods and the cell walls of fungi (Zhao et al., 2020). By comparing the structure of chitin with that of PGN, a component of bacterial cell walls, we observed that they have similar structures (Figure 2A). Based on this observation, we hypothesized that Chi3l1 may interact with gut bacteria through PGN. To test our hypothesis, we conducted co-incubation experiments where we mixed recombinant mouse Chi3l1 (rmChi3l1) with either Gram-positive or Gram-negative bacteria and then precipitated the bacteria through centrifugation. We found that rmChi3l1 was present in the pellet obtained from both Gram-positive and Gram-negative bacteria (Figure 2B), suggesting that Chi3l1 can directly interact with bacteria.
-
Figure 2—source data 1
- https://cdn.elifesciences.org/articles/92994/elife-92994-fig2-data1-v1.zip
-
Figure 2—source data 2
- https://cdn.elifesciences.org/articles/92994/elife-92994-fig2-data2-v1.zip
-
Figure 2—source data 3
- https://cdn.elifesciences.org/articles/92994/elife-92994-fig2-data3-v1.xlsx
To further investigate the interaction between Chi3l1 and PGN, we also co-incubated PGN with rmChi3l1 and precipitated the PGN through centrifugation. PGN is an insoluble substance and hence can be precipitated by centrifugation. Consistent with our previous results, we observed that rmChi3l1 was present in the pellet obtained from PGN but not in the pellet obtained from bovine serum albumin (BSA), which served as a negative control (Figure 2C). Furthermore, we also examined the interaction between PGN and recombinant human Chi3l1 (rhChi3l1) and obtained similar results (Figure 2D). These findings indicate that Chi3l1 interacts with bacteria through PGN.
To better characterize the binding between Chi3l1 and PGN, we compared the binding affinities of Chi3l1 to both PGN and chitin. We incubated chitin and PGN with rmChi3l1 in increasing doses (25, 50, 100 μg) and detected the precipitated rmChi3l1 by either chitin or PGN. Our results indicate that Chi3l1 interacts with PGN in a dose-dependent manner (Figure 2E). In contrast, the binding between Chi3l1 and chitin did not exhibit dose dependency (Figure 2E). These findings suggest a specific and distinct binding mechanism for Chi3l1 with PGN compared to chitin.
To investigate whether the Chi3l1-PGN interaction could facilitate the colonization of Gram-positive bacteria, we conducted adhesion experiments using DLD-1 cells and bacteria. We employed a GlmM mutant (PGN synthesis-deficient) and K12 bacteria (a wildtype E. coli strain used as a control) to assess their adhesion capabilities. The results showed that the adhesion ability of the GlmM mutant to cells significantly decreased (Figure 2F). Additionally, after knocking down Chi3l1 in DLD-1 cells (knockdown efficiency over 50%), we observed a decrease in bacterial adhesion (Figure 2G). These findings suggest that the Chi3l1-PGN interaction plays a crucial role in bacterial adhesion.
Intestinal bacteria are disordered in IEC∆Chil1 mice, especially Gram-positive bacteria
To gain initial insights into how the expression of Chi3l1 in IECs affects the colonization of gut microbiota, we created mice with a specific deficiency of Chi3l1 in IECs (referred to as IECΔChil1 mice) (Figure 3—figure supplement 1). We then conducted bacterial 16S rRNA sequencing analysis of the colon contents of both Villin-cre and IECΔChil1 littermates. Our analysis of alpha diversity revealed that the bacterial population was relatively lower in IECΔChil1 littermates compared to Villin-cre littermates (Figure 3A). This finding was further confirmed by conducting universal bacterial 16S rRNA qPCR analysis of the feces and ileum contents of IECΔChil1 and Villin-cre littermates, which also showed lower bacterial enrichment in IECΔChil1 mice (Figure 3B). Furthermore, principal component analysis demonstrated significant differences in bacterial diversity between Villin-cre and IECΔChil1 littermates (Figure 3C).
When we examined the relative abundance of Gram-positive and Gram-negative bacteria between Villin-cre and IECΔChil1 littermates, we observed that Gram-positive bacteria were significantly reduced in IECΔChil1 mice, while there was no notable difference in Gram-negative bacteria (Figure 3D). This result was further validated by staining lipoteichoic acid (LTA), a component present on Gram-positive bacteria, which revealed a lower abundance of Gram-positive bacteria in IECΔChil1 compared to Villin-cre littermates (Figure 3E). Moreover, visualization of Firmicutes by bacteria fluorescence in situ hybridization (FISH) staining, a dominant group of Gram-positive bacteria in the gut, also showed reduced levels of Firmicutes in the colon lumen of IECΔChil1 mice compared to Villin-cre mice (Figure 3F). Analysis of the relative abundance of specific Gram-positive bacterial species demonstrated a significant reduction in Lactobacillus in IECΔChil1 mice compared to Villin-cre mice (Figure 3G). Similar results were observed in Chil1-/- mice compared to wildtype mice (Figure 3H). Consist with the 16S rRNA sequencing analysis data, qPCR results showed that Turicibacter was more abundant in IECΔChil1 mice than Villin-cre mice (Figure 3—figure supplement 2). These findings suggest that Chi3l1 plays a role in regulating the colonization of Gram-positive bacteria, particularly Lactobacillus, in the murine gut.
Chi3l1 promotes the colonization of Gram-positive bacteria in intestinal mucus
Chi3l1 was found in secretory cells like goblet cells and Paneth cells, suggesting that it may be secreted into the intestinal lumen (Figure 1B). Immunohistochemistry staining of Chi3l1 in the colon revealed a large amount of Chi3l1 signals in the mucus layer (Figure 4A). Immunofluorescence co-staining of Chi3l1 with UEA-1 in the colon yielded similar results (Figure 4B). Furthermore, Chi3l1 was also detected in the ileum and colonic tissues and mucus layer (Figure 4C and D). These findings indicate that mouse Chi3l1 is specifically expressed in intestinal secretory epithelial cells and secreted into the intestinal lumen. Since large amounts of Chi3l1 is secreted into the mucus and Chi3l1 interact with bacteria, we hypothesize that Chi3l1 may regulate the colonization of Gram-positive bacteria in the mucus layer. To test this hypothesis, we isolated bacterial DNA from the ileum and colon mucus of both wildtype and Chil1-/- mice. Quantification of Gram-positive bacteria and Lactobacillus using qPCR revealed that both the ileum and colon mucus of Chil1-/- mice had significantly lower levels of Gram-positive bacteria and Lactobacillus compared to that of wildtype mice (Figure 4E and F).
-
Figure 4—source data 1
- https://cdn.elifesciences.org/articles/92994/elife-92994-fig4-data1-v1.zip
-
Figure 4—source data 2
- https://cdn.elifesciences.org/articles/92994/elife-92994-fig4-data2-v1.zip
-
Figure 4—source data 3
- https://cdn.elifesciences.org/articles/92994/elife-92994-fig4-data3-v1.xlsx
To further validate these results, we labeled a Gram-positive bacteria strain, Enterococcus faecalis, with fluorescent D-amino acids (FDAA), which can metabolically label bacterial PGNs (Wang et al., 2019). We then performed rectal injection of both wildtype and Chil1-/- mice with FDAA-labeled E. faecalis. The data demonstrated that Chil1-/- mice had much lower colonization of E. faecalis compared to wildtype mice (Figure 4G). Besides Gram-positive bacteria, we also performed rectal injection of both wildtype and Chil1-/- mice with mCherry-OP50 (a strain of E. coli that expresses mCherry), we found Chil1-/- mice had much higher colonization of E. coli compared to wildtype mice (Figure 4—figure supplement 1A). Based on these findings, we conclude that Chi3l1 promotes the colonization of Gram-positive bacteria, particularly Lactobacillus, in the intestinal mucus. Additionally, we also observed that the deletion of Chi3l1 significantly reduced mucus layer thickness, which may be attributed to the disrupted colonization of Gram-positive bacteria in the intestinal mucus layer (Figure 4—figure supplement 1B and C).
Disordered intestinal bacteria in IEC∆Chil1 mice contribute to colitis
From the above data, it is evident that Chi3l1 is secreted into the intestinal mucus to influence the colonization of Gram-positive bacteria, particularly Lactobacillus. We are now interested in understanding the role of Chi3l1-regulated microbiota in a pathological condition. We observed a significant increase in Chil1 mRNA expression in the colon tissues of patients with either CD or UC compared to normal tissues (Figure 5A). To investigate further, we created a colitis mouse model by subjecting Villin-cre and IEC∆Chil1 mice to a 2% dextran sodium sulfate (DSS) diet for 7 days (Figure 5B). The severity of colitis was assessed based on weight loss, colon length, and tissue damage. Without the DSS challenge, the colon length and structure were similar between Villin-cre and IEC∆Chil1 mice (Figure 5D and E). However, upon DSS challenge, the IEC∆Chil1 mice showed significantly shorter colon length, faster body weight loss, and more severe inflammation compared to the Villin-cre mice (Figure 5C–E).
To rule out the effects of Chi3l1 on the host contributed to colitis, we pretreated the mice with antibiotics to eliminate gut microbiota before inducing colitis (Figure 5—figure supplement 1A). The universal bacterial 16S rRNA qPCR data indicated that the majority of gut microbiota were eliminated after antibiotics treatment (Figure 5—figure supplement 1B). However, the IEC∆Chil1 mice exhibited a milder colitis phenotype, including slower body weight loss, longer colon length, and less inflammation compared to the Villin-cre mice (Figure 5—figure supplement 1C–E). We believe that this could be due to the relationship between Chi3l1 and inflammation. Based on these findings, it is apparent that Chi3l1’s effects on gut microbiota play a more significant role in colitis.
To further elucidate the role of Chi3l1-regulated gut microbiota in colitis, we conducted fecal microbiota transplantation (FMT) and Lactobacillus reuteri transplantation experiments. We first eliminated gut microbiota through a 10-day course of antibiotics and then performed FMT from Villin-cre mice or administered oral gavage of L. reuteri to IEC∆Chil1 mice for 2 weeks, followed by a 7-day period of 2% DSS feeding (Figure 5F). FMT partially restored the colon length of IEC∆Chil1 mice to that of Villin-cre mice after the DSS challenge, but did not have an impact on body weight loss or the level of inflammation in the gut (Figure 5G–I). IEC∆Chil1 mice transplanted with Lactobacillus displayed a similar colitis phenotype as Villin-cre mice, characterized by similar weight loss, colon length reduction, and gut inflammation (Figure 5G–I). These findings further validate the notion that Chi3l1-regulated gut microbiota, especially Lactobacillus, offers protection against colitis.
Discussion
The intricate relationship between gut bacteria and their host organisms is crucial for health, maintained through co-evolution and co-speciation. Understanding how the host influences these bacterial communities is critical to understand the complex interplay between host and gut bacteria. In this study, we discovered that Chi3l1 interacts with gut microbiota via PGN, aiding the mucus colonization of beneficial bacteria like Lactobacillus, which protects against colitis (Figure 6). Our ‘scaffold model’ demonstrates that Chi3l1 binds to bacterial PGN, helping anchor and organize bacteria within the mucus layer. This interaction promotes the colonization of beneficial bacteria, enhancing gut health.
Several studies have suggested a potential correlation between Chi3l1 and bacteria. For instance, it has been demonstrated that Chi3l1 is produced by IECs in enteritis disease and aids in the elimination of pathogenic bacteria in the gut by neutrophils (Deutschmann et al., 2019). Another study observed an increase in Chi3l1 expression in mammary tissues of dairy cows infected with pathogenic E. coli, which promoted the recruitment of neutrophils (Breyne et al., 2018). Furthermore, Chi3l1 was found to be induced during Streptococcus pneumoniae infection, where it enhanced bacterial elimination by preventing the death of lung macrophages and improving host tolerance (Dela Cruz et al., 2012). One study demonstrated that Chi3l1 contributes to the pathogenesis of colitis, possibly by facilitating the adhesion and invasion of bacteria onto colonic epithelial cells. However, we observed the presence of the Gram-negative bacterium Salmonella typhimurium in the mice used in their study (Mizoguchi, 2006). According to standard for SPF-grade mice, Salmonella should not be present in laboratory mice, and it was also not detected by our 16S RNA sequencing. However, if mice are inadvertently infected with Salmonella in the context of IBD, it could likely exacerbate the development of IBD. Our data also demonstrate that Chi3l1 can bind to Gram-negative bacteria (Figure 2B). Therefore, the role of Chi3l1 on microbiota or IBD is heavily dependent on the environmental context. Another study found that caffeine treatment reduce Chi3l1 RNA expression levels, alleviate colitis, and decrease bacterial translocation (Lee et al., 2014). However, previous research suggested that caffeine can directly inhibit inflammasome activation by suppressing MAPK/NF-κB signaling pathways (Vargas-Pozada et al., 2022). Therefore, caffeine treatment may directly reduce colitis by inhibiting inflammation. Moreover, an additional control group of mice with Chi3l1 specifically knocked out in the gut is needed to examine the role of caffeine in the alleviation of colitis. However, the detailed mechanism of the interaction between Chi3l1 and the gut microbiota remains incompletely understood, partly due to the absence of Chi3l1-specific knockout mice and variations in mouse husbandry conditions. Here, by using intestinal Chi3l1-specific knockout mice, we demonstrated a new function of Chi3l1 in gut, which shapes bacterial colonization through direct interaction with bacterial cell wall component, PGN. Moreover, Chi3l1-regulated gut microbiota, especially Lactobacillus, offers protection against colitis.
The bacterial cell wall is a complex structure mainly composed of PGN, but it may also contain other components such as teichoic acids and LTA in Gram-positive bacteria, or an outer membrane containing various polysaccharides, lipids, and proteins in Gram-negative bacteria (Zhou et al., 2022). Our findings indicated that LPS, a component of the bacterial cell wall, can slightly increase Chi3l1 expression (Figure 1F and G), but higher levels of LPS do not further enhance Chi3l1 expression (data not shown). This suggests that there might be other components of the cell wall that can induce Chi3l1 expression in IECs. Given the structural similarity between chitin and PGN (Figure 2A), it is likely that Chi3l1 binds to the polysaccharide chains rather than the tetrapeptide in PGN. Previous studies have investigated the crystal structure of human Chi3l1 in complex with chitin, revealing a binding groove with different subsites for chitin fragments (Fusetti et al., 2003). Other studies have also identified specific amino acids in chitinases that play a key role in the interaction with chitin (Ferrandon et al., 2003; Ranok et al., 2015). Nevertheless, further investigation is necessary to better understand the binding sites in Chi3l1 for PGN.
In the colon, there are two distinct parts of the mucus layer. The inner layer is attached and has a low number of microbes, while the outer layer is looser and densely populated by microorganisms. (Johansson et al., 2011). The diversity of bacteria in the mucus layer is similar to that found in the gut lumen (Hu et al., 2021). It has to be noted that not all Gram-positive bacteria were reduced in Chil1-/- mice, as we found an increase in Turicibacter in the colon (Figure 3G) and feces (data not shown). We believe this may be due to a combined effect of the host and gut microbiota. Another important factor for microbial growth in the colon is the integrity of the mucus barrier (Johansson et al., 2008). We noticed a thinning of the mucus barrier in the mice lacking Chi3l1 compared to normal mice (Figure 4—figure supplement 1B and C). However, we did not observe an increase in mucin-degrading bacteria such as Bacteroides or Allobaculum (Glover et al., 2022; Raimondi et al., 2021) or a decrease in mucin-producing cells in these mice. We think that there may be bacteria that aid in the formation of the gut mucus, and these bacteria are decreased in mice lacking Chi3l1. Recent studies have introduced an ‘ncapsulation model’ regarding the nature of mucus in the colon. According to this model, the mucus in the proximal colon forms a primary encapsulation barrier around fecal material, while the mucus in the distal colon forms a secondary barrier (Bergstrom et al., 2020). Our findings indicate that Chi3l1 is expressed throughout the entire colon, including the proximal, middle, and distal sections (data not shown). This suggests that Chi3l1 likely promotes bacterial colonization across the entire colon. Despite most mucus being expelled with feces, the constant production of mucus and the minimal presence of Chi3l1 in feces (Figure 4C) indicate that Chi3l1 continuously plays a role in promoting the colonization of microbiota.
In patients with IBD, the density and diversity of the microbial community in the intestines are reduced. Specifically, there is a decrease in Firmicutes and an increase in Bacteroides and facultative anaerobic bacteria like Enterobacteriaceae (Qin et al., 2010). However, the cause of colitis in IBD is still a subject of debate. Our data suggest that disruptions in the gut microbiota contribute to colitis. In summary, our study demonstrates that bacterial challenge induces the expression of Chi3l1 in IECs. Once produced, Chi3l1 is released into the mucus layer where it interacts with the gut microbiota, particularly through PGN, a primary component of bacterial cell walls. This interaction is beneficial for the colonization of bacteria, especially Gram-positive bacteria like Lactobacillus, in the mucus layer. Dysbiosis resulting from a lack of Chi3l1 exacerbates DSS-induced colitis, highlighting the role of dysbiosis as a contributing factor to colitis.
Materials and methods
Animal experiments and procedures
C57BL/6J (strain no. N000013), germ-free (strain no. N000295), Chil1fl/fl (strain no. T013652), and Chil1-/- (strain no. T014402) mice were purchased from GemPharmatech. Villin-cre mice were provided by Dr. Qun Lu (Yunnan University, China). All mouse colonies were maintained at the animal core facility of Yunnan University. C57BL/6J was used as wildtype control since Chil1-/- mice are on the C57BL/6J background, as determined by PCR (data not shown). The animal studies described have been approved by the Yunnan University Institutional Animal Care and Use Committee (IACUC, approval no. YNU20220256). Female mice aged 8–10 weeks old were used in most studies.
Genotyping
Request a detailed protocolTail clippings were placed in 1.5 mL tubes with 75 µL of master mix solution (60 µL H2O, 7.5 µL 250 mM NaOH, 7.5 µL 2 mM EDTA) and incubated at 98°C for 1 hr. After cooling to 15°C, 75 µL of neutralization buffer (40 mM Tris–HCl, pH 5.5) was added, and the samples were centrifuged at 4000 rpm for 3 min. A 1:10 dilution was prepared by mixing 2 µL of supernatant with 18 µL of water for genotyping PCR. A 25 µL PCR reaction mix was prepared with 12.5 µL of 2× Taq Master Mix (Dye Plus, Vazyme P112-03), 1 µL of each primer, 2 µL of template, and water. PCR was conducted using a Bio-Rad machine with the following program: 95°C for 5 min; 98°C for 30 s; 65°C with a 0.5°C decrement per cycle for 30 s; 72°C for 45 s, repeating steps 2–4 for 20 cycles; 98°C for 30 s; 55°C for 30 s; 72°C for 45 s, repeating steps 5–7 for 20 cycles; 72°C for 5 min; and hold at 10°C. Primer sequences are listed in Supplementary file 1.
Rectal administration of FDAA-labeled E. faecalis
Request a detailed protocolFor FDAA-labeled E. faecalis, E. faecalis were grown in LB media until reaching mid-exponential phase, approximately 4 hr. FDAA was then added to the culture media to a final concentration of about 17 µM. The E. faecalis continued to grow for 4 hr and were then harvested by centrifugation (5000 × g for 10 min), washed, and resuspended in PBS at a density of 5 × 109 CFU/mL. For rectal administration, wildtype and Chil1-/- mice were fasted overnight (5:00 pm to 9:00 am) before intraperitoneally (i.p.) injecting them with 400 mg/kg tribromoethanol (Nanjing AIBI BioTechnology, M2910), followed by rectal injection of 1 × 109 FDAA-labeled E. faecalis in 200 μL PBS via a flexible catheter. The catheter was inserted into the anus to a depth of 4.5 cm, and the E. faecalis were injected slowly to avoid overflow. The mice were then kept upside down for approximately 2 min. After 4 hr of rectal injection, the mice’s colons were collected and immediately embedded in OTC embedding medium for observation on 5-μm-thick frozen sections. OP50-mCherry (1 × 109 CFU/mice) were treated same as E. faecalis.
DSS-induced mouse colitis
Request a detailed protocolVillin-cre and IEC∆Chil1 mice were fed a 2% DSS (MP, 9011-18-1) solution in their drinking water for 7 days. The mice’s body weight was monitored daily during the feeding period. After the 7-day DSS treatment, the mice were sacrificed. Colons were collected, and their length was measured from the cecum to the rectum. Colon paraffin sections were harvested, and H&E staining was performed to examine gut inflammation.
Antibiotics treatment
Request a detailed protocolIEC∆Chil1 mice were fed an antibiotics mixture containing 0.5 mg/mL of metronidazole (Solarbio, M8060), 1 mg/mL of vancomycin (Solarbio, V8050), 1 mg/mL of ampicillin (Solarbio, A8180), and 0.5 mg/mL of neomycin sulfate (Solarbio, N8090) in their drinking water for 7 days (approximately 5 mL per mouse per day). After the 7-day antibiotics treatment, the mice were orally gavaged with 200 μL of the antibiotics mixture for another 3 days. Microbiota depletion was examined in feces using 16S rRNA qPCR on the tenth day of antibiotics feeding.
Fecal microbiota transplantation (FMT)
Request a detailed protocolFresh feces were collected from 8- to 10-week-old Villin-cre mice and immediately snap-frozen in liquid nitrogen. On the experimental day, feces were resuspended in PBS to a concentration of 200 mg/mL and centrifuged at 350 × g for 5 min to collect the supernatant. Antibiotics pre-treated IEC∆Chil1 mice were orally gavaged with 10 μL of the dissolved feces per gram of mouse weight for 14 days.
Oral gavage of Lactobacillus reuteri
Request a detailed protocolL. reuteri was grown in MRS broth at 37°C for 48 hr under anaerobic conditions. The bacteria were harvested by centrifugation (5000 × g for 10 min), washed, and resuspended in PBS at a density of OD605 = 1.2–1.3/mL. Antibiotics pre-treated IEC∆Chil1 mice were orally gavaged with 200 μL of the dissolved L. reuteri per mouse for 14 days.
Bacterial speciesidentification
Request a detailed protocolFresh feces were collected from 8-week-old wildtype mice and dissolved in LB culture medium. The dissolved feces were then cultured at 37°C for 12 hr and plated onto LB agar plates. The grown colonies were picked using sterile pipette tips and resuspended in 20 μL of sterile water. A PCR reaction was performed using 2 μL of the bacterial suspension as template DNA and universal bacterial 16S rRNA primers (27F, 5’-AGAGTTTGATCCTGGCTCAG-3’ and 1492R, 5’-GGTTACCTTGTTACGACTT-3’) with reaction conditions: 95°C for 5 min followed by 35 cycles of 95°C for 30 s, 55°C for 30 s, 72°C for 2 min and then 72°C for 20 min. The amplicons were then sequenced, and the resulting sequences were analyzed using BLASTN and the NCBI database for species identification.
Treatment of DLD-1 cells with live, heat-killed bacteria or LPS
Request a detailed protocolBacteria harvested from mouse feces or specific strains were grown in LB medium at 37°C for 12 hr under aerobic conditions. The bacteria were then collected by centrifugation (5000 × g for 10 min), washed, and resuspended in PBS at a density of 1.2 × 1010 CFU/mL. Live bacteria were used directly, while heat-killed bacteria required further heating at 80°C for 30 min. DLD-1 cells were grown in DMEM supplemented with 10% FBS. Prior to treatment, the cells were replated and allowed to reach 80% confluency. Either live or heat-killed bacteria were added to the cells at a multiplicity of infection (MOI) of 20 each well, and 100 pg/mL LPS treatment (Sigma, L4392; diluted in PBS) was also performed. After 12 hr incubation, cellular proteins were extracted for western blot analysis or the cells were subjected to immunofluorescent staining.
Cell culture and bacterial adhesion assay
Request a detailed protocolDLD-1 cells (ATCC CCL-221) were cultured in six-well plates until they reached approximately 80% confluency per well. The cells were then washed three times with PBS to remove any residual antibiotics. Fresh DMEM supplemented with 10% FBS (without antibiotics) was added to the cells. Absence of mycoplasma contamination was confirmed using PCR. E. coli strains were introduced to each well at an MOI of 20 and incubated for 2.5 hr at 37°C. After incubation, the cells were washed three times with PBS. For the adhesion assays, the cells were lysed with 1 mL of 1% Triton-X100 (BBI, 9002-93-1) in deionized water for 30 min. The cell lysates were then plated onto Luria broth (LB) agar plates at various dilutions and incubated overnight at 37°C. The following day, colonies were counted and calculated as CFU/mL.
shRNA lentivirus packaging and transfection
Request a detailed protocolFor the packaging of shRNA lentivirus, shRNA control and Chi3l1 shRNA1 lentiviruses were packaged in 293T cells. The cell culture medium containing the virus was collected and stored at –80°C. For transfection of DLD-1 cells, the cells were cultured in six-well plates until they reached approximately 80% confluency. The cell culture medium was then replaced with a mixture of culture medium containing the virus and fresh cell culture medium in a 1:1 ratio. Following transfection, the bacterial adhesion assay was performed as described above.
Bacterial or peptidoglycan binding assay
Request a detailed protocolDifferent bacteria strains were grown in LB medium at 37°C for 12 hr under aerobic conditions. The bacteria were collected by centrifugation (5000 × g for 10 min), washed, and resuspended in MES buffer (25 mM MES, 25 mM NaCl, pH = 6.0) at a density of 5 × 109 CFU/mL. 1 μg recombinant mouse Chi3l1 (rmChi3l1) was added to the bacterial suspension and incubated at 4°C under rotation overnight. Supernatant, wash fractions, and bacterial-bound fractions were collected and analyzed using western blot analysis. For the PGN binding assay, 1 μg rmChi3l1 or recombinant human Chi3l1 (rhChi3l1) and BSA was incubated with 100 μg PGN. The incubation and wash procedure were similar to the bacterial binding assay, and the proteins in each fraction were analyzed using silver staining or western blot.
Hematoxylin/eosin (H&E) and Periodic acid–Schiff and Alcian blue (AB-PAS) staining
Request a detailed protocolTissues were fixed with buffered 10% paraformaldehyde (BI, E672001-0500) overnight at 4°C and embedded in paraffin. Ultra-thin tissue slices (5 μm) were prepared and deparaffinized. H&E staining was performed on the tissue sections, and slides were examined under a microscope (Leica). For AB-PAS staining, tissues were fixed in Carnoy’s solution (60% ethanol, 30% chloroform, 10% acetic acid) for 24 hr at 4°C and embedded in paraffin. AB-PAS staining (Solarbio, G1285) was performed according to the manufacturer’s protocol. The staining was visualized under the microscope (Leica).
Immunohistochemical (IHC) and immunofluorescent (IF) staining
Request a detailed protocolTissue paraffin sections were prepared as previously described for H&E staining. Antigen retrieval was performed by treating the sections with citric acid (pH 6.0) at 95°C for 15 min, followed by cooling to room temperature. The sections were then washed with PBS and ddH2O. To block any nonspecific binding, a blocking buffer containing 5% goat serum, 3% BSA, and 0.1% Triton X-100 in PBS was applied to the sections for 1 hr at room temperature in a humidity chamber. The sections were then incubated with anti-Chi3l1 primary antibodies (Invitrogen, PA5-95897, 1:200), followed by staining with Goat anti-Rabbit IgG (H+L) Secondary Antibody-Biotin (Invitrogen, 65-6140, 1:2000). Finally, the sections were stained with Horseradish Peroxidase conjugate antibody (Invitrogen, A2664, 1:2000) and developed with DAB for 10 min. The slides were examined under a microscope (Leica).
Immunofluorescent staining was also performed on paraffin sections using specific primary antibodies. These included anti-MUC2 (Invitrogen, PA5-103083, 1:50), anti-Chi3l1 (Abcam, ab180569, 1:400; antigen retrieval with Tris-EDTA at pH 9.0), anti-ChgA (Santa Cruz, sc-393941, 1:200; antigen retrieval with citrate at pH 6.0), anti-UEA-1-FITC (GeneTeX, GTX01512, 1:200; antigen retrieval with citrate at pH 6.0), and anti-LTA (Invitrogen, MA1-7402, 1:50). The secondary antibodies used were 488-conjugated Affinipure Goat Anti-Rabbit IgG(H+L) (Jackson ImmunoResearch, 111-545-003, 1:1000) and 594-conjugated Goat Anti-Mouse IgG (H+L) (Jackson ImmunoResearch, 115-585-003, 1:1000). Slides were washed and mounted with antifade medium (Vectashield, H-1000-10). Nuclei were stained with DAPI (Beyotime, c1006, prediluted). Images were captured using a fluorescence microscope (Leica, 2084 DP-80).
For immunofluorescent staining on DLD-1 cells, cells were seeded on coverslips in 12-well plate and challenged with 100 pg/mL LPS (Sigma, L4391; diluted in PBS) for 12 hr. Cells were washed with cold PBS twice gently, then fixed with 2% paraformaldehyde in PBS at room temperature for 10 min. After removal of fixation buffer and wash twice with cold PBS, cells were blocked with blocking buffer (3% BSA, 0.5% Triton-X-100 in PBS) for 1 hr in humidity chamber at room temperature. Rabbit anti-Chi3l1 antibody (Proteintech, 12036-1-AP; 1:200) was applied at room temperature for 1 hr. After wash with 1× TBST three times, secondary antibody AlexaFluor 488 (Jackson ImmunoResearch, 111-545-003, 1:1000) was applied for another 1 hr at room temperature in a humidified chamber under darkness. Finally, cells were counterstained with DAPI (Beyotime, C1006) and mounted onto slides. Images were captured using an Olympus BX53F2 microscope.
Fluorescence in situ hybridization (FISH)
Request a detailed protocolMurine intestinal paraffin sections were prepared according to the previously described method for H&E staining. The tissues sections were rehydrated using a graded ethanol series and then washed with distilled water. The Gram-positive bacterial probe, consisting of three different sequences (/5Alex550N/TGGAAGATTCCCTACTGC/3AlexF550N/, /5Alex550N/CGGAAGATTCCCTACTGC/3AlexF550N/, /5Alex550N/CCGAAGATTCCCTACTGC/3AlexF550N/), or the control nonspecific probe (/5Alex550N/ACTCCTACGGGAGGCAGC/3AlexF550N/), was diluted to a concentration of 100 nM in FISH hybridization buffer (containing 20 mM Tris pH 7.2, 0.9 M NaCl, and 0.1% SDS) and applied to the slides. The slides were then incubated overnight at 56°C in a humidified chamber. Following incubation, the slides were washed and the nuclei were counterstained with DAPI. The images were captured using a fluorescence microscope (Leica, 2084 DP-80).
Immunoblot and silver staining
Request a detailed protocolProtein extraction from cultured cells involved lysing the cells in 2% SDS lysis buffer, which is prepared by dissolving 2 g of SDS powder in 100 mL of sterilized ddH2O. Bacteria or PGN precipitates were resuspended in MES buffer, which contained 25 mM MES, 25 mM NaCl, and had a pH of 6.0. For protein extraction from mice ileum and colon tissues, 30 mg of snap-frozen tissues were homogenized in 1 mL of RIPA buffer, which contained 10 mM Tris–HCl (pH 8.0), 1 mM EDTA, 0.5 mM EGTA, 1% TritonX-100, 0.1% sodium deoxycholate, 0.1% SDS, 140 mM NaCl, 1 mM PMSF, and a proteinase inhibitor. The lysates were then supplemented with 5× SDS loading buffer to a final concentration of 1×. The resulting mixture was subsequently boiled at 100°C for 10 min and centrifuged at 4°C and 12,000 rpm for 10 min. The supernatants were collected for western blot analysis. The supernatants were separated using a 10% SDS-PAGE gel and then transferred to a polyvinylidene fluoride membrane. The membranes were blocked with 5% nonfat milk in TBST buffer (containing 0.1% Tween-20 in Tris-buffered saline) and sequentially incubated with primary antibodies and appropriate horseradish peroxidase (HRP)-conjugated secondary antibodies. Protein bands were detected using enhanced chemiluminescence (ECL) reagent with a Minichemi Chemiluminescence Imaging System. The primary antibodies used included anti-Chi3l1 (RD, MAB2649, 1:2000), anti-alpha-Actinin (Cell Signaling, 69758S, 1:1000), rabbit anti-Chi3l1 antibody (Proteintech, 12036-1-AP, 1:2000), and mouse anti-α-tubulin antibody (Sigma, T5168, 1:2000). The secondary antibodies used were goat anti-Rat-IgG (Cell Signaling, 7077S, 1:10,000), goat anti-mouse (Invitrogen, 62-6520, 1:10,000) and Goat anti-Rabbit IgG (Jackson ImmunoResearch, 111-035-0030, 1:10,000). For silver staining, the PAGE gel was subjected to silver staining using a fast-silver staining kit (Beyotime, P0017S) following the manufacturer’s instructions.
DNA extraction for 16S rRNA analysis
Request a detailed protocolFor isolation of luminal contents from murine ileum and colon, a 9 cm section of ileum and 3 cm section of colon were cut open longitudinally, and luminal contents were scratched off into a pre-weighed 2 mL sterile freezing vial. The weight of the contents was recorded for further processing. For isolation of mucus from murine ileum and colon, tissues were flushed with 2 mL of ice-cold PBS into a pre-weighed 2 mL sterile freezing vial after removal of the liminal contents. The mucus was then pelleted by centrifugation at 10,000 × g for 10 min, and the supernatant was removed. For feces isolation, fresh murine feces were collected into a sterile freezing vial weighing 2 mL and immediately snap-frozen in liquid nitrogen. For bacterial DNA extraction, DNA was extracted and purified following the manufacture’s protocol using the EIANamp stool DNA kit (TIANGEN, DP328-02).
Microbiota 16S rRNA gene sequencing
Request a detailed protocolFecal samples, ileum contents, and colon contents were collected from wildtype, Chil1-/- littermates, or Villin-cre, IEC∆Chil1 littermates and immediately frozen in liquid nitrogen. The microbial genomic DNA was extracted and 16S rRNA sequencing was performed by Biomarker Technologies. The hypervariable regions V3 and V4 of the bacterial 16S rRNA gene were sequenced using universal primers that flank these regions V3 (338F 5'-ACTCCTACGGGAGGCAGCA-3') and V4 (806R 5'- GGACTACHVGGGTWTCTAAT-3’). The sequencing was done using the IIIumina Sequencing platform. The resulting 16S rRNA gene sequences were analyzed using scripts from the BMK Cloud platform (https://www.biocloud.net/). The microbial classification was performed using the SILVA138 and hierarchical clustering algorithms. The OTUs were determined by clustering the sequences with 97% similarity and were classified into different taxonomic ranks. The relative abundance of each bacterial species was visualized using R software. The raw 16S rRNA gene sequencing data can be accessed on the BMKCloud platform under the project ID Microbial_updateReport_20211221092022313.
16S qPCR analysis
Request a detailed protocolQuantitative PCR was performed using SYBR green master mix (Thermo Fisher, A25742) in triplicates. This was done on a Real-Time PCR QuatStudio1 with accompanying software, following the instructions provided by the manufacturer (Life Technologies, Grand Island, NY). The abundance of specific bacterial groups in the intestine was determined using qPCR with either universal or bacteria-specific 16S rRNA gene primers. Standard curves were constructed with E. coli OP50 16S rRNA gene, which was amplified using conserved 16S rRNA primers. It should be noted that qPCR measures the number of 16S gene copies per sample, not the actual bacterial numbers or colony forming units. Primer sequences are provided in Supplementary file 1.
Statistical analysis
Request a detailed protocolData were presented as mean ± SEM. Statistical analyses were carried out using GraphPad Prism (GraphPad Software). Comparisons between two groups were carried out using unpaired Student’s t-test. Comparisons among multiple groups (n ≥ 3) were carried out using one-way or two-way ANOVA. Data are presented as mean ± SEM, and p<0.05 was considered a significant difference, *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001, ‘ns’ represents no significant difference.
Data availability
Sequencing data have been deposited in NCBI under accession codes PRJNA1155018 and PRJNA1157557. All data generated or analyzed during this study are included in the manuscript and supporting files; source data files have been provided for all figures.
-
NCBI BioProjectID PRJNA1155018. Identification of intestinal contents and fecal bacteria in mice.
-
NCBI BioProjectID PRJNA1157557. Bacterial microbial diversity in mouse stool.
-
NCBI Gene Expression OmnibusID GSE165512. Characterization of the IL23-IL17 immune axis in IBD patients.
References
-
Identification of chitinase-3-Like Protein 1 as a novel neutrophil antigenic target in crohn’s diseaseJournal of Crohn’s & Colitis 13:894–904.https://doi.org/10.1093/ecco-jcc/jjz012
-
A single surface tryptophan in the chitin-binding domain from Bacillus circulans chitinase A1 plays A pivotal role in binding chitin and can be modified to create an elutable affinity tagBiochimica et Biophysica Acta - General Subjects 1621:31–40.https://doi.org/10.1016/S0304-4165(03)00029-1
-
Loss of intestinal core 1-derived O-glycans causes spontaneous colitis in miceThe Journal of Clinical Investigation 121:1657–1666.https://doi.org/10.1172/JCI45538
-
Crystal structure and carbohydrate-binding properties of the human cartilage glycoprotein-39The Journal of Biological Chemistry 278:37753–37760.https://doi.org/10.1074/jbc.M303137200
-
The treatment-naive microbiome in new-onset Crohn’s diseaseCell Host & Microbe 15:382–392.https://doi.org/10.1016/j.chom.2014.02.005
-
Co-evolution and co-speciation of host-gut bacteria systemsCell Host & Microbe 28:12–22.https://doi.org/10.1016/j.chom.2020.06.013
-
Structure and ligand-induced conformational change of the 39-kDa glycoprotein from human articular chondrocytesThe Journal of Biological Chemistry 278:30206–30212.https://doi.org/10.1074/jbc.M303371200
-
Role of chitin and chitinase/chitinase-like proteins in inflammation, tissue remodeling, and injuryAnnual Review of Physiology 73:479–501.https://doi.org/10.1146/annurev-physiol-012110-142250
-
Application of ecological and evolutionary theory to microbiome community dynamics across systemsProceedings. Biological Sciences 287:20202886.https://doi.org/10.1098/rspb.2020.2886
-
Defining dysbiosis and its influence on host immunity and diseaseCellular Microbiology 16:1024–1033.https://doi.org/10.1111/cmi.12308
-
Identification of mucin degraders of the human gut microbiotaScientific Reports 11:11094.https://doi.org/10.1038/s41598-021-90553-4
-
Structural and thermodynamic insights into chitooligosaccharide binding to human cartilage chitinase 3-like protein 2 (CHI3L2 or YKL-39)The Journal of Biological Chemistry 290:2617–2629.https://doi.org/10.1074/jbc.M114.588905
-
Spatial organization and composition of the mucosal flora in patients with inflammatory bowel diseaseJournal of Clinical Microbiology 43:3380–3389.https://doi.org/10.1128/JCM.43.7.3380-3389.2005
-
Caffeine Inhibits NLRP3 Inflammasome Activation by Downregulating TLR4/MAPK/NF-κB Signaling Pathway in an Experimental NASH ModelInternational Journal of Molecular Sciences 23:9954.https://doi.org/10.3390/ijms23179954
-
Chitinase-3 like-protein-1 function and its role in diseasesSignal Transduction and Targeted Therapy 5:201.https://doi.org/10.1038/s41392-020-00303-7
-
Breaking down the cell wall: Still an attractive antibacterial strategyFrontiers in Microbiology 13:952633.https://doi.org/10.3389/fmicb.2022.952633
Article and author information
Author details
Funding
Ministry of Science and Technology of the People's Republic of China (2019YFA0803100)
- Bin Qi
National Natural Science Foundation of China (32071129)
- Zhao Shan
National Natural Science Foundation of China (32170794)
- Bin Qi
Yunnan Provincial Science and Technology Department (202101AT070022)
- Zhao Shan
Yunnan Provincial Science and Technology Department (202201AT070196)
- Bin Qi
Science and Technological Talent Cultivation Plan of Yunnan Province (C619300A086)
- Zhao Shan
Science and Technological Talent Cultivation Plan of Yunnan Province (K264202230211)
- Bin Qi
Yunnan Provincial Science and Technology Project at Southwest United Graduate School (202302AP370005)
- Bin Qi
Ministry of Science and Technology of the People's Republic of China (2019YFA0802100)
- Bin Qi
Yunnan Provincial Science and Technology Department (202001AW070006)
- Zhao Shan
The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.
Acknowledgements
We thank Qun Lu (Yunnan University) for providing Villin-cre mice. We thank Wenxiang Fu (Yunnan University) for imaging technical support. We thank Jianwei Sun (Yunnan University) for providing DLD-1 cell line. We thank Zehan Hu (Shanghai Jiao Tong University) for methods of bacteria 16S FISH staining. This work was supported by the Ministry of Science and Technology of China (2019YFA0803100, 2019YFA0802100 to BQ), National Natural Science Foundation of China (32071129 to ZS, 32170794 to BQ), Yunnan Fundamental Research Projects (202101AT070022, 202001AW070006 to ZS, 202201AT070196 to BQ), Science and Technological Talent Cultivation Plan of Yunnan Province (C619300A086 to ZS, K264202230211 to BQ), and Yunnan Provincial Science and Technology Project at Southwest United Graduate School (202302AP370005 to BQ).
Ethics
The animal studies described have been approved by the Yunnan University Institutional Animal Care and Use Committee (IACUC, Approval No. YNU20220256).
Version history
- Sent for peer review:
- Preprint posted:
- Reviewed Preprint version 1:
- Reviewed Preprint version 2:
- Version of Record published:
Cite all versions
You can cite all versions using the DOI https://doi.org/10.7554/eLife.92994. This DOI represents all versions, and will always resolve to the latest one.
Copyright
© 2024, Chen, Yang et al.
This article is distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use and redistribution provided that the original author and source are credited.
Metrics
-
- 770
- views
-
- 103
- downloads
-
- 0
- citations
Views, downloads and citations are aggregated across all versions of this paper published by eLife.
Download links
Downloads (link to download the article as PDF)
Open citations (links to open the citations from this article in various online reference manager services)
Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)
Further reading
-
- Immunology and Inflammation
Chronic antigenic stimulation can trigger the formation of interleukin 10 (IL-10)-producing T-regulatory type 1 (TR1) cells in vivo. We have recently shown that murine T-follicular helper (TFH) cells are precursors of TR1 cells and that the TFH-to-TR1 cell transdifferentiation process is characterized by the progressive loss and acquisition of opposing transcription factor gene expression programs that evolve through at least one transitional cell stage. Here, we use a broad range of bulk and single-cell transcriptional and epigenetic tools to investigate the epigenetic underpinnings of this process. At the single-cell level, the TFH-to-TR1 cell transition is accompanied by both, downregulation of TFH cell-specific gene expression due to loss of chromatin accessibility, and upregulation of TR1 cell-specific genes linked to chromatin regions that remain accessible throughout the transdifferentiation process, with minimal generation of new open chromatin regions. By interrogating the epigenetic status of accessible TR1 genes on purified TFH and conventional T-cells, we find that most of these genes, including Il10, are already poised for expression at the TFH cell stage. Whereas these genes are closed and hypermethylated in Tconv cells, they are accessible, hypomethylated, and enriched for H3K27ac-marked and hypomethylated active enhancers in TFH cells. These enhancers are enriched for binding sites for the TFH and TR1-associated transcription factors TOX-2, IRF4, and c-MAF. Together, these data suggest that the TR1 gene expression program is genetically imprinted at the TFH cell stage.
-
- Genetics and Genomics
- Immunology and Inflammation
Systemic lupus erythematosus (SLE) is an autoimmune disease, the pathophysiology and genetic basis of which are incompletely understood. Using a forward genetic screen in multiplex families with SLE, we identified an association between SLE and compound heterozygous deleterious variants in the non-receptor tyrosine kinases (NRTKs) ACK1 and BRK. Experimental blockade of ACK1 or BRK increased circulating autoantibodies in vivo in mice and exacerbated glomerular IgG deposits in an SLE mouse model. Mechanistically, NRTKs regulate activation, migration, and proliferation of immune cells. We found that the patients’ ACK1 and BRK variants impair efferocytosis, the MERTK-mediated anti-inflammatory response to apoptotic cells, in human induced pluripotent stem cell (hiPSC)-derived macrophages, which may contribute to SLE pathogenesis. Overall, our data suggest that ACK1 and BRK deficiencies are associated with human SLE and impair efferocytosis in macrophages.